Dr. Srinivasan Jayakumar
Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, Troy, Alabama, USA
Postdoctoral Research Associate
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
11Years (2016-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications16 September 2016 in ChemistrySelect
Journal Article
SSS. Samundeeswari
S. Samundeeswari
MKManohar Kulkarni
Manohar KulkarniSJShrinivas D. Joshi
Shrinivas D. Joshi
DDDr. Sheshagiri Ravindra Dixit
Dr. Sheshagiri Ravindra DixitSrinivasan JayakumarRER. M. Ezhilarasi
R. M. Ezhilarasi
22 December 2023 in Journal of Neurochemistry
Journal Article
RCRyan Cantwell Chater
Ryan Cantwell ChaterAQAda S. Quinn
Ada S. QuinnKWKatie Wilson
Katie WilsonZFZachary J. Frangos
Zachary J. Frangos
PSPatrick Sutton
Patrick Sutton
Robert Vandenberg +3
Glycine Transporter 2 (GlyT2) inhibitors have shown considerable potential as analgesics for the treatment of neuropathic pain but also display considerable side effects. One potential source of side effects is irreversible inhibition. In this study, we have characterized the mechanism of ORG25543 inhibition of GlyT2 by first considering three potential ligand binding sites on GlyT2—the substrate site, the vestibule allosteric site and the lipid allosteric site. The three sites were tested using a combination of molecular dynamics simulations and analysis of the inhibition of glycine transport of a series point mutated GlyT2 using electrophysiological methods. We demonstrate that the lipid allosteric site on GlyT2 is the most likely binding site for ORG25543. We also demonstrate that cholesterol derived from the cell membrane can form specific interactions with inhibitor‐bound transporters to form an allosteric network of regulatory sites. These observations will guide the future design of GlyT2 inhibitors with the objective of minimising on‐target side effects and improving the therapeutic window for the treatment of patients suffering from neuropathic pain. image
17 June 2021 in Journal of Medicinal Chemistry
Journal Article
CCChristopher L. Cioffi
Christopher L. CioffiARArun Raja
Arun Raja
PMParthasarathy Muthuraman
Parthasarathy Muthuraman
AJAravindan Jayaraman
Aravindan Jayaraman
Srinivasan JayakumarKPKonstantin Petrukhin
Konstantin Petrukhin +2
Journal Article
NGNitesh K. Gupta
Nitesh K. GuptaSrinivasan JayakumarJHJih Ru Hwu
Jih Ru HwuPLPieter Leyssen
Pieter LeyssenJNJohan Hendrik Neyts
Johan Hendrik NeytsSTShwu-Chen Tsay
Shwu-Chen Tsay +2
The yellow fever virus (YFV) is an emerging RNA virus and has caused large outbreaks in Africa and Central and South America. The virus is often transmitted through infected mosquitoes and spreads from area to area because of international travel. Being an acute viral hemorrhagic disease, yellow fever can be prevented by an effective, safe, and reliable vaccine, but not be eliminated. Currently, there is no antiviral drug available for its cure. Thus, two series of novel bis(benzofuran–1,3-imidazolidin-4-one)s and bis(benzofuran–1,3-benzimidazole)s were designed and synthesized for the development of anti-YFV lead candidates. Among 23 new bis-conjugated compounds, 4 of them inhibited YFV strain 17D (Stamaril) on Huh-7 cells in the cytopathic effect reduction assays. These conjugates exhibited the most compelling efficacy and selectivity with an EC50 of 15.3. The results are valuable for the development of novel antiviral drug leads against emerging diseases.
19 July 2023 in ACS Chemical Neuroscience
Journal Article
CGCasey I. Gallagher
Casey I. Gallagher
ZFZachary J. Frangos
Zachary J. FrangosDSDiba Sheipouri
Diba Sheipouri
SSSusan Shimmon
Susan Shimmon
MDMeryem-Nur Duman
Meryem-Nur Duman
Robert Vandenberg +3
Journal Article
Jih Ru HwuDPDr. Avijit Panja
Dr. Avijit PanjaSrinivasan JayakumarSTShwu-Chen Tsay
Shwu-Chen TsayKKui Thong Tan
Kui Thong Tan JNJohan Hendrik Neyts
Johan Hendrik Neyts +3
The modern world has no available drugs for the treatment of enteroviruses (EV), which affect millions of people worldwide each year. The EV71 is a major causative disease for hand, foot, and mouth disease; sometimes it is associated with severe central nervous system diseases. Treatment for enteroviral infection is mainly supportive; treatment for aseptic meningitis caused by enteroviruses is also generally symptomatic. Upon the urgent request of new anti-enterovirus drugs, a series of hinged aromatic compounds with polynulei were synthesized through two different chemical pathways. Among these morpholine–furan/thiophene/pyrrole–benzene–pyrazole conjugates, three new agents exhibited inhibitory activity with EC50 = 2.29–6.16 μM toward EV71 strain BrCr in RD cells. Their selectivity index values were reached as high as 33.4. Their structure–activity relationship was deduced that a thiophene derivative with morpholine and trifluorobenzene rings showed the greatest antiviral activity, with EC50 = 2.29 μM.
About Me
Dr. Srinivasan Jayakumar is an accomplished Postdoctoral Research Associate currently affiliated with the Rensselaer Polytechnic Institute in New York, USA. He specializes in Synthetic Organic and Medicinal Chemistry, bringing over eight years of detailed research experience which includes five years of Industrial experience at Syngene International Pvt Ltd, India. Dr. Jayakumar's educational background includes a Ph.D. in Organic Chemistry from National Tsing Hua University, Taiwan, and a Master’s in chemistry from Guru Nanak College, University of Madras, India. In 2020, he transitioned to the U.S., undertaking a postdoctoral research position at Albany College of Pharmacy and Health Sciences, NY, and is currently engaged with Rensselaer Polytechnic Institute in Troy, NY. Dr. Jayakumar's notable research focuses on developing GlyT2 inhibitors for the treatment of neuropathic pain and RBP4 antagonists for the treatment of age-related macular degeneration, Transthyretin Amyloidosis, and their Common Age-related comorbidities.
In addition to his research work, Dr. Jayakumar actively contributes to the scientific community. He is not only a member of the American Chemical Society and Sigma Xi but also serves on the editorial boards of several international chemistry journals and has a strong track record as a journal peer reviewer.
Social Links
